Why is Sandu Pharmaceuticals Ltd falling/rising?

Recent Price Movement and Market Context

Sandu Pharmaceuticals has demonstrated a robust upward trajectory over the past week, gaining 7.67% compared to the Sensex’s marginal decline of 0.30% during the same period. This outperformance extends to the month-to-date figures as well, with the stock appreciating 2.03% while the Sensex fell by 0.88%. Year-to-date, the stock’s gains mirror its weekly performance, indicating sustained buying interest since the start of the calendar year.

Despite this recent momentum, it is important to note that the stock’s longer-term performance remains subdued. Over the past year, Sandu Pharmaceuticals has declined by 27.37%, contrasting sharply with the Sensex’s 8.65% gain. Similarly, over three and five years, the stock has underperformed the benchmark by a wide margin, reflecting challenges in maintaining consistent growth over extended periods.

Intraday and Technical Indicators

On 07-Jan, the stock reached an intraday high of ₹40.50, marking a 7.03% increase from previous levels. This intraday strength underscores the positive sentiment among traders and investors. The stock’s current price sits above its 5-day and 20-day moving averages, signalling short-term bullishness. However, it remains below the 50-day, 100-day, and 200-day moving averages, suggesting that medium to long-term technical resistance levels have yet to be overcome.

Interestingly, the weighted average price indicates that a larger volume of shares traded closer to the day’s low price, which may imply some caution among participants despite the overall price rise. Additionally, investor participation appears to be waning, with delivery volume on 06-Jan plunging by 97.07% compared to the five-day average. This sharp drop in delivery volume could indicate that fewer investors are holding shares for the long term, favouring short-term trading strategies instead.

Liquidity and Trading Dynamics

Liquidity remains adequate for Sandu Pharmaceuticals, with the stock’s traded value representing approximately 2% of its five-day average. This level of liquidity supports reasonable trade sizes without causing significant price disruption. However, the sharp decline in delivery volumes suggests that while the stock is actively traded, the commitment of investors to hold shares beyond intraday or short-term horizons is limited.

The stock’s recent consecutive gains over two days, amounting to a 6.9% return, further highlight the current positive momentum. This short-term rally has enabled the stock to outperform its sector by 6.41% on the day, signalling relative strength within its industry group.

Balancing Short-Term Gains Against Long-Term Challenges

While the recent price appreciation is encouraging, investors should weigh this against the stock’s longer-term underperformance. The significant declines over one, three, and five years relative to the Sensex indicate structural challenges that the company has yet to fully overcome. The current rally may be driven by short-term factors such as technical buying and sector rotation rather than fundamental improvements.

Moreover, the subdued investor participation and trading volumes near the lower price range suggest that the rally could be fragile and susceptible to reversal if broader market conditions or company-specific news turn negative. Investors should monitor whether the stock can sustain gains above key moving averages and attract stronger delivery volumes to confirm a more durable uptrend.

In summary, Sandu Pharmaceuticals Ltd’s share price rise on 07-Jan is primarily attributable to short-term positive momentum, sector outperformance, and technical factors. However, the stock’s longer-term performance and cautious trading patterns advise prudence for investors considering exposure at current levels.

Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →